MEDIVIR is a Swedish biotech company.[1] Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.[2] Medivir is listed on the Nasdaq Stockholm Mid Cap List.
